The Ca2+-activated K+ channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Chen, Yi Je ^a   Lam, Jenny ^a   Gregory, Clare R ^b   Schrepfer, Sonja ^c,d   Wulff, Heike ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY HEART CENTER HAMBURG   (Germany)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; CALCIUM ACTIVATED POTASSIUM CHANNEL; COLLAGEN; GAMMA INTERFERON; POTASSIUM CHANNEL KV1.3;

ADULT; ANIMAL EXPERIMENT; AORTA GRAFT; ARTERY INTIMA PROLIFERATION; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; FIBROBLAST; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; MALE; MEMORY T LYMPHOCYTE; MONONUCLEAR CELL; NONHUMAN; PATHOGENESIS; RAT; RESTENOSIS; SMOOTH MUSCLE;

ALLOGRAFTS; AMINOPEPTIDASES; ANIMALS; COLLAGEN; GENE EXPRESSION; GRAFT REJECTION; HUMANS; INTERFERON-GAMMA; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; KV1.3 POTASSIUM CHANNEL; MALE; ORGAN TRANSPLANTATION; PYRAZOLES; RATS; TUNICA INTIMA; VASCULAR DISEASES;

EID: 84896730049     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081006     Document Type: Article

References (52)

1. Mitchell RN, Libby P (2007) Vascular remodeling in transplant vasculopathy. Circ Res 100: 967-978. (Pubitemid 46598921)
2. Rahmani M, Cruz RP, Granville DJ, McManus BM (2006) Allograft vasculopathy versus atherosclerosis. Circ Res 99: 801-815. (Pubitemid 44556379)
3. Lu WH, Palatnik K, Fishbein GA, Lai C, Levi DS, et al. (2011) Diverse morphologic manifestations of cardiac allograft vasculopathy: a pathologic study of 64 allograft hearts. J Heart Lung Transplant 30: 1044-1050.
4. Libby P, Tanaka H (1994) The pathogenesis of coronary arteriosclerosis ("chronic rejection") in transplanted hearts. Clin Transplant 8: 313-318.
5. van Loosdregt J, van Oosterhout MF, Bruggink AH, van Wichen DF, van Kuik J, et al. (2006) The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response. Circulation 114: 1599-1607.
6. Furukawa Y, Libby P, Stinn JL, Becker G, Mitchell RN (2002) Cold ischemia induces isograft arteriopathy, but does not augment allograft arteriopathy in non-immunosuppressed hosts. Am J Pathol 160: 1077-1087. (Pubitemid 34224594)
7. Nagano H, Libby P, Taylor MK, Hasegawa S, Stinn JL, et al. (1998) Coronary arteriosclerosis after T-cell-mediated injury in transplanted mouse hearts: role of interferon-gamma. Am J Pathol 152: 1187-1197. (Pubitemid 28221872)
8. Cahalan MD, Chandy KG (2009) The functional network of ion channels in T lymphocytes. Immunol Rev 231: 59-87.
9. + channel in effector memory T cells as new target for MS. J Clin Invest 111: 1703-1713.
10. Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, et al. (2006) Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci USA 103: 17414-17419. (Pubitemid 44788983)
11. + channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem Rev 108: 1744-1773.
12. Wulff H, Castle NA, Pardo LA (2009) Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov 8: 982-1001.
13. Tarcha EJ, Chi V, Munoz-Elias EJ, Bailey D, Londono LM, et al. (2012) Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease. J Pharmacol Exp Ther.
14. Wulff H, Castle NA (2010) Therapeutic potential of KCa3.1 blockers: recent advances and promissing trends. Expert Rev Clin Pharmacol 3: 385-396.
15. Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, et al. (2005) Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol 68: 1254-1270. (Pubitemid 41539982)
16. + channel, IKCa1: A potential immunosuppressant. Proc Natl Acad Sci USA 97: 8151-8156.
17. Azam P, Sankaranarayanan A, Homerick D, Griffey S, Wulff H (2007) Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol 127: 1419-1429. (Pubitemid 46762978)
18. Kohler R, Wulff H, Eichler I, Kneifel M, Neumann D, et al. (2003) Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation 108: 1119-1125. (Pubitemid 37071524)
19. Tharp DL, Wamhoff BR, Wulff H, Raman G, Cheong A, et al. (2008) Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis. Arterioscler Thromb Vasc Biol 28: 1084-1089.
20. Grgic I, Kiss E, Kaistha BP, Busch C, Kloss M, et al. (2009) Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proc Natl Acad Sci USA 106: 14518-14523.
21. Toyama K, Wulff H, Chandy KG, Azam P, Raman G, et al. (2008) The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest 118: 3025-3037.
22. Deuse T, Hoyt G, Koyanagi T, Robbins RC, Schrepfer S (2008) Prevention and inhibition but not reversion of chronic allograft vasculopathy by FK778. Transplantation 85: 870-877. (Pubitemid 351440753)
23. Mennander A, Tiisala S, Halttunen J, Yilmaz S, Paavonen T, et al. (1991) Chronic rejection in rat aortic allografts. An experimental model for transplant arteriosclerosis. Arterioscler Thromb 11: 671-680.
24. Schmid C, Binder J, Heemann U, Tilney NL (1994) Successful heterotopic heart transplantation in rat. Microsurgery 15: 279-281. (Pubitemid 24177608)
25. Schmid C, Heemann U, Tilney NL (1997) Factors contributing to the development of chronic rejection in heterotopic rat heart transplantation. Transplantation 64: 222-228. (Pubitemid 27332662)
26. Lehr HA, Mankoff DA, Corwin D, Santeusanio G, Gown AM (1997) Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 45: 1559-1565. (Pubitemid 27465476)
27. Lambertsen KL, Gramsbergen JB, Sivasaravanaparan M, Ditzel N, Sevelsted-Moller LM, et al. (2012) Genetic KCa3.1-deficiency produces locomotor hyperactivity and alterations in cerebral monoamine levels. PLoS One 7: e47744.
28. Chen YJ, Raman G, Bodendiek S, O'Donnell ME, Wulff H (2011) The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J Cereb Blood Flow Metab 31: 2363 - 2374.
29. Ca3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease. Br J Pharmacol 168: 432-444.
30. Kenyon NJ, Ward RW, Last JA (2003) Airway fibrosis in a mouse model of airway inflammation. Toxicol Appl Pharmacol 186: 90-100. (Pubitemid 36298618)
31. null T cells in patients with acute coronary syndrome. Clin Immunol 142: 209-217.
32. Brahler S, Kaistha A, Schmidt VJ, Wolfle SE, Busch C, et al. (2009) Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation 119: 2323-2332.
33. Ghanshani S, Wulff H, Miller MJ, Rohm H, Neben A, et al. (2000) Up-regulation of the IKCa1 potassium channel during T-cell activation: Molecular mechanism and functional consequences. J Biol Chem 275: 37137-37149. (Pubitemid 32002132)
34. Deuse T, Schrepfer S, Reichenspurner H (2003) Immunosuppression with FK778 and mycophenolate mofetil in a rat cardiac transplantation model. Transplantation 76: 1627-1629. (Pubitemid 37549839)
35. Deuse T, Schrepfer S, Reichenspurner H (2004) The interaction between FK778 and tacrolimus in the prevention of rat cardiac allograft rejection is dose dependent. Transplantation 77: 509-513. (Pubitemid 38282803)
36. Deuse T, Hua X, Taylor V, Stubbendorff M, Baluom M, et al. (2012) Significant reduction of acute cardiac allograft rejection by selective Janus kinase-1/3 inhibition using R507 and R545. Transplantation 94: 695-702.
37. + channel in vascular smooth muscle: relationship between KCa channel diversity and smooth muscle cell function. Circ Res 85: e33-e43.
38. Cheong A, Bingham AJ, Li J, Kumar B, Sukumar P, et al. (2005) Downregulated REST transcription factor is a switch enabling critical potassium channel expression and cell proliferation. Mol Cell 20: 45-52. (Pubitemid 41396561)
39. Kumar B, Dreja K, Shah SS, Cheong A, Xu SZ, et al. (2006) Upregulated TRPC1 channel in vascular injury in vivo and its role in human neointimal hyperplasia. Circ Res 98: 557-563.
40. 2+ pump in proliferating human arterial myocytes. Am J Physiol Cell Physiol 297: C1103-1112.
41. Jackson WF (2005) Potassium channels and proliferation of vascular smooth muscle cells. Circ Res 97: 1211-1212.
42. Bi D, Toyama K, Lemaitre V, Takai J, Fan F, et al. (2013) The intermediate conductance calcium-activated potassium channel KCa3.1 regulates vascular smooth muscle cell proliferation via controlling calcium-dependent signaling. J Biol Chem 288: 15843-15853.
43. Pena TL, Chen SH, Konieczny SF, Rane SG (2000) Ras/MEK/ERK Upregulation of the fibroblast KCa channel FIK is a common mechanism for basic fibroblast growth factor and transforming growth factor-beta suppression of myogenesis. J Biol Chem 275: 13677-13682. (Pubitemid 30257437)
44. Cheong A, Li J, Sukumar P, Kumar B, Zeng F, et al. (2011) Potent suppression of vascular smooth muscle cell migration and human neointimal hyperplasia by KV1.3 channel blockers. Cardiovasc Res 89: 282-289.
45. Cidad P, Moreno-Dominguez A, Novensa L, Roque M, Barquin L, et al. (2010) Characterization of ion channels involved in the proliferative response of femoral artery smooth muscle cells. Arterioscler Thromb Vasc Biol 30: 1203-1211.
46. Jackson WF (2010) KV1.3: a new therapeutic target to control vascular smooth muscle cell proliferation. Arterioscler Thromb Vasc Biol 30: 1073-1074.
47. Ataga KI, Orringer EP, Styles L, Vichinsky EP, Swerdlow P, et al. (2006) Dose-escalation study of ICA-17043 in patients with sickle cell disease. Pharmacotherapy 26: 1557-1564. (Pubitemid 44704467)
48. Ataga KI, Smith WR, De Castro LM, Swerdlow P, Saunthararajah Y, et al. (2008) Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 111: 3991-3997.
49. Hua X, Deuse T, Chen Y-J, Wulff H, Köhler R, et al. (2013) The potassium channel KCa3.1 as new therapeutic target for preventing obliterative airway disease after lung transplant. Transplantation 95: 285-292.
50. Grgic I, Wulff H, Eichler I, Flothmann C, Kohler R, et al. (2009) Blockade of T-lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection. Transplant Proc 41: 2601-2606.
51. + channel KCa3.1 ameliorates T cell-mediated colitis. Proc Natl Acad Sci USA 107: 1541-1546.
52. +channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model. Am J Respir Cell Mol Biol 48: 212-219.